Literature DB >> 25727646

Evaluating competing and emerging technologies for stereotactic body radiotherapy and other advanced radiotherapy techniques.

A G R Martin1, S J Thomas2, S V Harden3, N G Burnet4.   

Abstract

Stereotactic body radiotherapy (SBRT) refers to the precise irradiation of an image-defined extracranial lesion, using a high total radiation dose delivered in a small number of fractions. A significant proportion of SBRT treatment has been successfully delivered using conventional gantry-based linear accelerators with appropriate image guidance and motion management techniques, although a number of specialist systems are also available. Evaluating the competing SBRT technologies is difficult due to frequent refinements to all major platforms. Comparison of geometric accuracy or treatment planning performance can be hard to interpret and may not provide much useful information. Nevertheless, a general specification overview can provide information that may help radiotherapy providers decide on an appropriate system for their centre. A number of UK randomised controlled trials (RCTs) have shown that better radiotherapy techniques yield better results. RCTs should play an important part in the future evaluation of SBRT, especially where there is a smaller volume of existing data, and where outcomes from conventional radiotherapy are very good. RCT comparison of SBRT with surgery is more difficult due to the radically different treatment arms, although successful recruitment can be possible if the lessons from previous failed trials are learned. The evaluation of new technology poses a number of challenges to the conventional RCT methodology, and there may be situations where it is genuinely not possible, with careful observational studies or decision modelling being more appropriate. Further development in trial design may have an important role in providing clinical evidence in a more timely manner.
Copyright © 2015 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Keywords:  Clinical trials; dosimetry; stereotactic ablative radiotherapy; stereotactic body radiotherapy

Mesh:

Year:  2015        PMID: 25727646     DOI: 10.1016/j.clon.2015.01.034

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  7 in total

Review 1.  A systematic review of outcomes following stereotactic ablative radiotherapy in the treatment of early-stage primary lung cancer.

Authors:  Patrick Murray; Kevin Franks; Gerard G Hanna
Journal:  Br J Radiol       Date:  2017-02-17       Impact factor: 3.039

2.  Benchmark Credentialing Results for NRG-BR001: The First National Cancer Institute-Sponsored Trial of Stereotactic Body Radiation Therapy for Multiple Metastases.

Authors:  Hania A Al-Hallaq; Steven J Chmura; Joseph K Salama; Jessica R Lowenstein; Susan McNulty; James M Galvin; David S Followill; Clifford G Robinson; Thomas M Pisansky; Kathryn A Winter; Julia R White; Ying Xiao; Martha M Matuszak
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-09-28       Impact factor: 7.038

3.  53BP1/RIF1 signaling promotes cell survival after multifractionated radiotherapy.

Authors:  Iris Eke; Dali Zong; Molykutty J Aryankalayil; Veit Sandfort; Michelle A Bylicky; Barbara H Rath; Edward E Graves; André Nussenzweig; C Norman Coleman
Journal:  Nucleic Acids Res       Date:  2020-02-20       Impact factor: 16.971

4.  Where is clinical research for radiotherapy going? Cross-sectional comparison of past and contemporary phase III clinical trials.

Authors:  Sunmin Park; Chai Hong Rim; Won Sup Yoon
Journal:  Radiat Oncol       Date:  2020-02-14       Impact factor: 3.481

Review 5.  Evolution of Stereotactic Ablative Radiotherapy in Lung Cancer and Birmingham's (UK) Experience.

Authors:  Sundus Yahya; Qamar Ghafoor; Robert Stevenson; Steven Watkins; Beshar Allos
Journal:  Medicines (Basel)       Date:  2018-07-23

Review 6.  Interaction between Fibroblasts and Immune Cells Following DNA Damage Induced by Ionizing Radiation.

Authors:  Kalaiyarasi Ragunathan; Nikki Lyn Esnardo Upfold; Valentyn Oksenych
Journal:  Int J Mol Sci       Date:  2020-11-16       Impact factor: 5.923

7.  Diffusion of innovation in radiation oncology in the United States.

Authors:  Patricia Sansourekidou; Vasileios Margaritis; Wen-Hung Kuo
Journal:  BJR Open       Date:  2020-08-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.